Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies
- Determine the feasibility and efficacy of cisplatin, doxorubicin, and tamoxifen (CAT)
in patients with soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer,
or adrenal cancer.
- Determine the toxicity of this regimen in these patients.
OUTLINE: Patients receive cisplatin IV over 1-2 hours followed immediately by doxorubicin IV
over 15-30 minutes on days 1-3 and oral tamoxifen twice daily on days 4-17. Treatment
continues every 3 weeks in the absence of the total cumulative doxorubicin dose reaching at
least 500 mg/m2, disease progression, or unacceptable toxicity. Patients who achieve partial
remission (PR) undergo local surgery or radiotherapy, if feasible, to convert PR to complete
Patients are followed every 2 months for 1 year and then every 3 months for 2 years.
PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Stan Z. Gertler, MD, FRCPC
Ottawa Regional Cancer Centre
United States: Federal Government